Mitchell Mcleod Pugh & Williams Inc. Has $963,000 Stake in Becton, Dickinson and Company (NYSE:BDX)

Mitchell Mcleod Pugh & Williams Inc. increased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 1.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,951 shares of the medical instruments supplier’s stock after purchasing an additional 49 shares during the quarter. Mitchell Mcleod Pugh & Williams Inc.’s holdings in Becton, Dickinson and Company were worth $963,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in BDX. Ontario Teachers Pension Plan Board lifted its stake in Becton, Dickinson and Company by 242.8% in the third quarter. Ontario Teachers Pension Plan Board now owns 1,783,769 shares of the medical instruments supplier’s stock valued at $461,158,000 after acquiring an additional 1,263,391 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Becton, Dickinson and Company by 2.0% in the third quarter. Vanguard Group Inc. now owns 25,927,519 shares of the medical instruments supplier’s stock valued at $6,703,041,000 after purchasing an additional 516,427 shares during the period. Massachusetts Financial Services Co. MA raised its position in shares of Becton, Dickinson and Company by 11.0% in the third quarter. Massachusetts Financial Services Co. MA now owns 5,192,832 shares of the medical instruments supplier’s stock valued at $1,342,503,000 after purchasing an additional 512,566 shares during the period. Royal Bank of Canada raised its position in shares of Becton, Dickinson and Company by 28.5% in the third quarter. Royal Bank of Canada now owns 2,139,493 shares of the medical instruments supplier’s stock valued at $553,121,000 after purchasing an additional 473,914 shares during the period. Finally, Morgan Stanley raised its position in shares of Becton, Dickinson and Company by 4.5% in the third quarter. Morgan Stanley now owns 10,200,213 shares of the medical instruments supplier’s stock valued at $2,637,062,000 after purchasing an additional 435,168 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

NYSE:BDX traded up $2.75 during mid-day trading on Monday, reaching $234.30. 182,781 shares of the company’s stock were exchanged, compared to its average volume of 1,352,679. The firm has a market capitalization of $67.69 billion, a PE ratio of 54.87, a price-to-earnings-growth ratio of 1.91 and a beta of 0.43. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.64 and a current ratio of 1.08. Becton, Dickinson and Company has a one year low of $229.40 and a one year high of $287.32. The business’s fifty day simple moving average is $239.24 and its two-hundred day simple moving average is $241.10.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, February 1st. The medical instruments supplier reported $2.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.39 by $0.29. The firm had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.73 billion. Becton, Dickinson and Company had a net margin of 6.44% and a return on equity of 13.57%. The business’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same period in the prior year, the company posted $2.98 earnings per share. Analysts anticipate that Becton, Dickinson and Company will post 12.94 earnings per share for the current fiscal year.

Insider Activity

In other news, SVP Thomas J. Spoerel sold 282 shares of the firm’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $238.29, for a total value of $67,197.78. Following the sale, the senior vice president now directly owns 2,276 shares in the company, valued at approximately $542,348.04. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.31% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on BDX shares. Barclays increased their price objective on shares of Becton, Dickinson and Company from $301.00 to $305.00 and gave the company an “overweight” rating in a research report on Monday, February 5th. Raymond James raised their price target on shares of Becton, Dickinson and Company from $269.00 to $275.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 3rd. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, Becton, Dickinson and Company has an average rating of “Moderate Buy” and an average target price of $280.00.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.